Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article Demonstrating Advancement in the Company’s Technology to Treat Diabetes

Kadimastem

Kadimastem (TASE: KDST), a clinical stage biotechnology company announced today that the peer-reviewed journal Frontiers in Endocrinology has published an article in a focused issue on advances in stem cell technology to model and treat diabetes (click here to access the full article). The article describes the results of collaborative research conducted by Kadimastem’s R&D team in concert with scientists from the Weizmann Institute of Science. The article details the important milestones achieved thus far in the pre-clinical development of Kadimastem’s diabetes product, IsletRx, and their translation to clinical application. IsletRx is composed of clinical grade pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels. Using micro-encapsulation technology, integrated within IsletRx, the islet cells are protected from an attack response by the host immune system. The article details the advantages of Kadimastem’s novel selection and purification process technology currently utilized in the production of IsletRx. By employing Functional Cell-Capture Screening (FCCS) technology, the scientists identified unique signature cell-surface markers that enable them to select and enrich the IsletRx product with a population of highly effective cells. The selection process also eliminates cells that may not be necessary for function, and even may impair the efficacy and/or the safety of the transplanted cells. These results position IsletRx as a potential cure for many insulin dependent diabetes patients. Kadimastem has renewed its focus on the advances in its diabetes project and its strategic positioning among other leading cell therapy companies worldwide. The Company’s technology is singular in its ability to refine the composition of Islet cells differentiated from hPSC by negative selection to remove un-needed cells and positive selection for selecting highly functional insulin producing cells to achieve the maximum therapeutic effect. “The implications of this proprietary technology developed by our team and the WIS scientists, could be tremendously important in developing effective therapies for hundreds of millions of people living with diabetes,” said Asaf Shiloni, Chief Executive Officer of Kadimastem. “We are immensely proud of the work of our scientific team, led by Kadimastem Chief Scientist and Israel Prize winner Professor Michel Revel. His vision guides the research presented in this important article and the work provides a solid foundation to continue advancing Kadimastem’s mission to develop and provide a cell therapy cure for diabetes.” Dr. Kfir Molakandov, head of Kadimastem’s diabetes cell therapy program said, “The research results published in Frontiers in Endocrinology will enable an improved and safer cell therapy product development. We have managed to demonstrate that we have the capability to manufacture the islets in a good, reproducible way and our proof-of-concept studies show that treatment with IsletRx is capable of ameliorating glycaemia in diabetic animals for a prolonged period of time.” Social Media: LinkedIn, Twitter, Facebook Company Contacts: Asaf Shiloni CEO info@kadimastem.com Press Contact: Marjie Hadad General Manager Must Have Communications 917-790-1178 marjie@mhc-pr.com About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Asaf Shiloni +972 73-797-1613 a.shiloni@kadimastem.com Company Website https://www.kadimastem.com/

May 11, 2021 07:00 AM Eastern Daylight Time

Image

New Markets Tax Credit Coalition Advocates for Permanency

New Markets Tax Credit Coalition

The week of May 10, 2021, will serve as Advocacy Week for the New Markets Tax Credit (NMTC) Coalition. Members of the NMTC Coalition will be contacting Members of Congress about the importance of the NMTC and its permanency during virtual visits with Representatives and Senators. In particular, they will be advocating for the NMTC in regards to President Biden’s American Jobs Plan in hopes of creating effective policy changes. Specifically, Coalition members are asking their Members of Congress to do the following: Enact a permanent extension of NMTC along the lines of the Bipartisan NMTC Extension Act of 2021; Provide $15 million in technical assistance support and ensure that at least 5 percent of annual NMTC allocation is available for new and emerging Minority Led Community Development Entities; Ensure that at least $500 million in NMTC annual allocation is used to expand investment in Indian Country; Promote greater economic growth in economically distressed rural, urban and tribal communities by providing an additional $3 billion in NMTC allocation for investment in child care facilities, clean technology industries, small business incubators and other infrastructure investments; and Include provisions to improve investor liquidity. “Over the last 20 years the NMTC has proven to be an essential tool for creating jobs, improve facilities and services and business and economic opportunity in communities left out of the economic mainstream,” said Bob Rapoza, NMTC Coalition Spokesperson. “There is no better way to enact the American Jobs Plan than through such a program, which will undoubtedly help underserved and marginalized communities for the better. We hope to impress upon Members of Congress the importance of the NMTC and how it can be integrated with the American Jobs Plan during the upcoming Advocacy Week.” Many of the goals and priorities within the American Jobs Plan directly align with the New Markets Tax Credit – particularly its emphasis on supporting underserved communities. The NMTC is targeted to low-income census tracts in rural and urban communities. Every year, between 75-80 percent of NMTC activity is in high distress communities – with poverty rates above 20 percent, median incomes lower than 60 percent of area median and/or unemployment rates 1.5 times the national average. Over 50 percent of NMTC activity to date is in majority-minority communities. Supporting the American Jobs Plan goals through expanded use of the NMTC would ensure that infrastructure spending reaches underserved communities and supports historically disadvantaged groups within an established, existing federal program with robust reporting metrics, well-tested programmatic rules and administration, and established agency infrastructure within the Treasury Department at the CDFI Fund. About New Markets Tax Credit Program The New Markets Tax Credit (NMTC) was enacted in 2000 in an effort to stimulate private investment and economic growth in low-income urban neighborhoods and rural communities that lack access to the patient capital needed to support and grow businesses, create jobs, and sustain healthy local economies. Since its inception, the NMTC has generated more than one million jobs. Today, due to the NMTC, nearly $110 billion is hard at work in underserved communities in all 50 states, the District of Columbia, and Puerto Rico. For more information, visit www.NMTCCoalition.org. Contact Details Greg Wilson +1 571-239-7474 greg@curleycompany.com Company Website http://nmtccoalition.org/

May 06, 2021 09:00 AM Eastern Daylight Time

Graphic novel tackles disinformation around COVID-19 Vaccine and critical 5G infrastructure

Stockwood Strategy

Sophisticated social media campaigns sponsored by bad state actors are responsible for creating and spreading disinformation around the critical Covid-19 Vaccine and emerging infrastructure such as 5G technology for communications. Erly Stage Studios has today published Bug Bytes, the digital graphic novel, which sheds a light on the disruptive forces at work. This book is the second installment of the graphic novels that are a part of the Resilience Series commissioned by the US Cyber Infrastructure and Security Agency (CISA). Bug Bytes will inform and educate people on the dangers and risks associated with dis- and mis- information through fictional stories inspired by real-world events. In Bug Bytes, readers will meet the protagonist Ava Williams, a journalist and academic, patriot and member of Symous - a group fighting disinformation and foreign interference in elections as polling day approaches. Ava’s life gets tangled up in a web of lies as her father, a 5G technician gets hurt and she works to understand what a seemingly innocent poll online related to 5G technology has to do with the 5G Vaccine? Ava is surprised by the reaction of the anti-vaccination community at what is proven to be engineered data and has the unenviable task of making the case to the public at large for how they can be weary on data online with unproven provenance. Farid Haque, founder and CEO of Erly Stage Studios commented: “We’re delighted to have been commissioned by CISA to create a practical and engaging communication tool that highlights the existential threat of disinformation in the context of bad state actors. While the story is fictional many of the approaches shown are very much grounded in the reality of the technology we live with and are exposed to almost daily.” Bug Bytes provides a unique education for the reader about the world of social media and how digital resources can be hijacked to serve a more nefarious agenda. The ability for foreign bad state actors to weld this kind of influence on another nation is unprecedented as is their ability to twist and manipulate a narrative to use domestic groups to do their bidding. The work helps the reader understand the need to exercise care when it comes to consuming news and information via social media platforms and online sources of information. In the story, Ava Williams and a team of patriots are racing against the clock to shine a spotlight on the source of disinformation engineered to hurt critical communication infrastructure and damage the Vaccine roll-out efforts. Ava’s investigative journalism leads her through the metaverse to find allies and discovers through hard graft that foreign actors are tinkering with public data to maliciously mislead and influence perceptions of 5G as a communications technology and its fabricated link to vaccine effectiveness. “Bug Bytes is the culmination of the wealth of experience that Clint Watts brings in cyber warfare and disinformation and our studio’s creative direction and storytelling style. We spent months researching the real life incidents and then wrapped them into a fictional story” added Farid Haque. The graphic novel is being made available by CISA to the general public online as a free resource as the Covid19 vaccine roll out continues to have an impact across the United States and the world at large. The work is available for free for the public and media to read at the following URL: https://www.cisa.gov/cfi-resilience-series-graphic-novels. A first title in the series was released a few months earlier last year ahead of the US elections titled Real Fakes. Watch this space and log back into https://publishing.erlystagestudios.com/ to learn more. Contributing artists to Bug Bytes include: Jose Niño Galenzoga, Patricia Beja, Mona Shan and Joel Santiago. Lettering and layouts by Komal N. and Haroon M. Story by Clint Watts and Farid Haque, supported by the script writing team which includes Michael Gianfrancesco and Kabir Sabharwal. Edited by Tolly M. and Laila Khan. Special thanks to Randall Heather and Max Brooks. Erly Stage Studios is an indie publisher, headquartered out of London, United Kingdom, capturing iconic stories in serious graphic novels. We are an expert team of educators, storytellers, and artists working to create awareness about important topics using the graphic novel medium. The team loves shining a spotlight on stories that are yet to see the light of graphic novels. As an expert team of teachers, researchers and designers the team works with innovative organisations and policymakers around the world to deliver soft power through engaging and creative projects. Contact Details Erly Stage Studios Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://publishing.erlystagestudios.com/

May 06, 2021 05:00 AM Eastern Daylight Time

Image

The First American Samurai With Divine Purpose

Koyamada International Foundation

The Last Samurai star Shin Koyamada and wife of 16 years, Nia Lyte, tried everything possible to get pregnant, but dishearteningly, nothing worked. As time slipped by and Nia’s biological clock started ticking, the odds of pregnancy became overwhelmingly against them. The couple tried many rounds of IVF treatments with top fertility doctors in different countries, reiki, yoga, acupuncture, Tibetan meditation, natural herbs, hormone stimulation, astrology, and a cosmos analysis to see if the ancestors were interfering, yet all techniques failed. With each defeat, the Koyamada’s spirits waned, fear and anxiety increased. A miscarriage almost sealed the decision of starting a natural family simply would not happen. After the miscarriage crisis, when Nia and Shin went to Japan, their Shintoist Japanese friend, who had a similar journey, said that a spiritual person told the couple to beseech the Virgin Mary on their behalf. Coming from a Japanese Shintoist, Nia was taken aback by the recommendation and yet touched when she met her friend’s miracle daughter. Back in Los Angeles and during the dawn of the pandemic, Nia joined a small Christian Bible group, and Nia and the group prayed together for a baby. Nia got pregnant three months later. Nia boldly recalled, “This changed our family. It is different when you read about miracles or see them in films. When you experience a miracle in your own flesh, it is very powerful. I made a promise to God that if He could give us a baby, I would share this miracle with the world. I would also give Jesus and his mother Virgin Mary all the glory. It may sound crazy, but when everything else failed, the power of prayer worked for our family.” In early 2021, little Shun Nathan Koyamada entered into Shin and Nia’s lives. Not giving up on each other, sticking it out together, and overcoming the trauma of five long years, Shin and Nia further proved that marriage truly is not always about looking at each other but looking in the same direction. Proud father Shin shares that the name Shun is derived from his ancestors, the Hayato People who lived in the Satsuma Domain, today's Kagoshima Prefecture located at the southern most area of Japan's Kyushu Island, where 900+ years ago the name came into use by the samurai under the title Hayato no suke. Nia added that Nathan means gift from God. Shin discovered his samurai ancestry via his grandfather, telling him old stories based on the grandfather's life-long research on the subject. Surprisingly, Shin didn't know his samurai ancestry until after the release of the Hollywood blockbuster Last Samurai, a film influenced by the 1877 Satsuma Rebellion, where Shin's character Nobutada Katsumoto, inspired by his real samurai ancestor, befriends Tom Cruise's Algren role. Apart from his samurai descendants, Shun's unique heritage includes being half Colombian, half Japanese, and the first American samurai born in the United States. As Nobutada might say, "Jolly Good.” According to Shin and Nia, doctors said that since science should have worked but failed, she had a two percent chance of having a healthy natural pregnancy. They concurred that Nia giving birth to a biological baby was a medical miracle. Shun is a miracle baby and is proof to the Koyamadas of a higher power in charge. For Shin and Nia, having a baby completes the circle in their lives. After co-founding KIF ( Koyamada International Foundation ), a nonprofit organization dedicated to inspiring youth and women to achieve their dreams. Now for the Koyamadas, their work takes on added meaning beyond being symbolic. It is now more personal. KIF can create miracles for others. Because after their personal miracle, the Koyamadas have the strength of three spirits: dad, Shin; mum, Nia; and son, Shun. Follow Nia and Shin on social media Facebook @NiaLyteShow and @shinkoyamada, Twitter @nialyte and @shinkoyamada, Instagram @nialyte and @ shin_koyamada. For interviews and media inquiries, contact Kelly Bennett at Bennett Unlimited PR at (949) 463-6383 or Kelly@BennettUnlimitedPR.com. Contact Details BENNETT UNLIMITED PR Kelly Bennett +1 949-463-6383 kelly@bennettunlimitedpr.com Company Website http://koyamada.org

May 05, 2021 02:02 AM Eastern Daylight Time

Image

Shreesha Ramdas to join CIPIO’s Advisory Board to hyper accelerate growth

CIPIO.ai

CIPIO, a B2C Subscription Success company, today announced that Shreesha Ramdas has joined its board of advisors. Ramdas currently serves as SVP and GM for Medallia-owned Strikedeck – a powerful customer success automation solution. Prior to Medallia, Ramdas co-founded Leadformix, a marketing automation platform acquired by CallidusCloud in 2012. A seasoned entrepreneurial executive with a proven track record of launching and rapidly scaling automation solutions for customer success and marketing, Ramdas is constantly on the lookout for the “next big thing” in the customer engagement world – an attitude that led him to join CIPIO’s advisory board. Customer churn is a rampant reality in the B2C Subscription industry, given how easy it is for customers to downgrade, switch, or cancel service providers in a matter of just a few clicks. Industry study suggests that 96% of B2C Subscription businesses believe their customers churn for reasons that could have been prevented, managed, or fixed. Post Covid, Net Revenue Retention (NRR), and Customer Retention have become strategic priorities for B2C Subscription companies and will continue to become table stakes over time. According to Bain and Company, increasing customer retention rates by just 5% increases 25% profits for B2C Subscription companies. “In a world where the bar for customer engagement keeps going higher, I love how CIPIO is redefining customer retention - making it actionable, easy and impactful for B2C Subscription companies through its Data Apps,” said Ramdas. “The SaaS landscape continues to explode with solutions, yet there are literally very few solutions solving NRR and Customer Retention for the B2C Subscription companies. With its code-free Enterprise AI and Domain-Infused Data Apps Platform™, CIPIO offers the precise action to drive measurable results for B2C Subscription companies.” With the B2C Subscription Economy expected to be valued at a whopping $478 billion by 2025, it is surprising that the industry’s churn rate is two times that of the B2B SaaS Economy. CIPIO’s Domain-Infused Data Apps Platform™ aims to tip this balance back and level the playing field. “I’m ecstatic to have Shreesha onboard as we move full-speed into our next phase of growth and innovation. The hybrid economy is here, and you can no longer hope to just focus on acquisition as it costs five times as much to attract a new customer than to keep an existing one,” said Growson Edwards, Co-Founder, and CEO of CIPIO. “Our mission is to enable B2C Subscription companies to proactively prevent churn and achieve higher Net Retention Rate for consistent growth. Shreesha’s obsession and tremendous experience in launching customer success solutions and product experience will accelerate our product innovation yielding higher returns for our customers.” About CIPIO CIPIO is pioneering the Industry's first domain-infused Data Apps Platform™ that humanizes and automates predictions and recommendations to increase Subscriber engagement, retention, and growth for B2C Subscription Companies. CIPIO's early adopters include Crunch Fitness, Industry's Gym, Xponential Fitness, Motor City Church, Pure Barre, Club Pilates, AKT, YogaSix, NCFit, Cyclebar, RowHouse, Stretch Lab, and Stride who have witnessed a significant return on investment in a short time. Contact Details CIPIO Chris Foudy +1 831-238-1905 chris@cipio.ai Company Website https://cipio.ai/

May 04, 2021 02:20 PM Eastern Daylight Time

Cloudrise Honored as Gold Stevie® Award Winner

Cloudrise

Cloudrise was named the winner of a Gold Stevie® Award in the Tech Startup of the Year – Services category in The 19 th Annual American Business Awards®. More than 3,800 nominations – a record number - from organizations of all sizes and in virtually every industry were submitted this year for consideration in a wide range of categories. As the Gold medal recipient in the category of “ Tech Startup of the Year – Services ”, Cloudrise was heralded by the judges: “Cloudrise’s data-centric approach to cybersecurity, and use of automation, are very much needed services for organizations to enable the digital transformation journey.” Cloudrise was founded in October 2019, and in 2020 they conquered the seemingly impossible, launching a new company amidst a global pandemic and economic downturn. Despite those challenges, Cloudrise had a successful year one in business, exceeding 2020 revenue targets, securing capital investments through investors, and delivering Managed Services and Security Process Automation to over 50 customers. Cloudrise’s CEO, Rob Eggebrecht, shared his thoughts about what makes Cloudrise different: “Cloudrise’s Security Process Automation services are a key differentiator in the marketplace. Organizations are dependent on data stored within a myriad of systems, requiring integration and automation to enable them to work at the speed of business. Cloudrise automates operational processes across data protection and privacy solutions, business applications, and visualization tools, to optimize manual processes, enhance reporting, and provide faster incident response. Starting with an assessment, we identify use cases, develop playbooks, and ultimately build, deploy, and manage the automation.” About the American Business Awards The American Business Awards are the U.S.A.’s premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small. Nicknamed the Stevies for the Greek word meaning “crowned,” the awards will be virtually presented to winners during a live event on Wednesday, June 30. Tickets for the virtual event are now on sale. More than 250 professionals worldwide participated in the judging process to select this year’s Stevie Award winners. “The American economy continues to show its resilience, and as we’re poised on the beginning of what should be a phenomenal period of growth, we celebrate the remarkable achievements of a wide range of organizations and people over the past 18 months,” said Stevie Awards president Maggie Gallagher. “This year’s Stevie-winning nominations in The American Business Awards are testament to the ingenuity, the commitment, the passion, the adaptability, and the creativity of the American people.” Details about The American Business Awards and the list of 2021 Stevie winners are available at www.StevieAwards.com/ABA. About the Stevie Awards Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com. Sponsors of The 2021 American Business Awards include John Hancock Financial Services, Melissa Sones Consulting, and SoftPro. About Cloudrise Cloudrise was founded by business and security entrepreneurs with experience in global markets, successful start-ups, and Fortune 500 companies. Combining decades of data protection expertise with automation, Cloudrise focuses on securing data wherever it resides. They assist organizations by assessing, enabling, automating, and managing their data protection and privacy programs. At Cloudrise, they are redefining data protection. Cloudrise can be found at www.cloudrise.com or on LinkedIn. Contact Details Jodi Lewis +1 800-917-7619 sales@cloudrise.com Company Website https://cloudrise.com/

May 04, 2021 11:11 AM Central Daylight Time

How To Reduce Social Security Taxes In Retirement by Jennifer Lang Financial Services

Jennifer Lang Financial Services, LLC

Contact Details Jennifer Lang Financial Services, LLC. Jennifer Lang +1 877-487-8926 mail@jenniferlangfinancialservices.com Company Website https://www.jenniferlangfinancialservices.com

May 04, 2021 10:05 AM Eastern Daylight Time

Video

CereMetrix Corp. Introduces Enhancements to its Advanced Medical Imaging and Analytics Platform

CereHealth

CereMetrix Corp., a wholly owned subsidiary of data analytics technology company CereHealth Corp., has released an enhanced version of its imaging platform, CereMetrixAi™. Using its FDA-cleared QSPECT ® analysis as a template, the platform can now incorporate additional imaging, such as MRI, PET and CT, and non-imaging analytical assessments through an expanding catalog of both in-house and third-party medical image algorithms. Its improved integration capabilities for data collection and reporting opens the door for broader use of non-imaging assessments like neuropsychological evaluations and cognitive screens and expands the platform’s clinical and research applications. CereMetrixAi™ is a browser-based, cloud-enabled, HIPAA-compliant imaging platform that features FDA-cleared QSPECT® analysis. The platform offers accessible, automated, and objective imaging to radiologists and treating providers to detect, quantify and analyze in significantly less time than other reading tools, and at significantly less expense than traditional workstation-based software solutions. Now with its open platform architecture, various sources of imaging and non-imaging data can be analyzed in a templated, customizable report that is available to clinicians and their patients anytime, anywhere through a browser. The new release offers efficiency and user experience enhancements to radiologists through inherent support for overreads, customizable templated language fields and a new interface for annotations and image capture. It also allows other medical imaging modalities such as MRI, PET and CT to take advantage of the three-dimensional visualization capabilities that were previously offered solely with SPECT brain studies. Third party imaging developers may now deliver their products to the market via CereMetrixAi’s browser-based platform, expanding the visualization options available and providing doctors a more complete path toward accurate diagnoses. “Our vision of bringing data driven medical imaging and analytics to healthcare professionals worldwide takes a giant leap forward with the introduction of CereMetrix 2.0,” said Shane Quint, Chief Technology Officer of CereHealth Corp. “By integrating all sources and types of patient data in a user-friendly platform we are enabling a more complete picture of an individual’s health for more effective diagnosis and treatment. It is the definition of Precision Medicine, and we are proud to be a leader in software solutions that make sense for patients, providers and researchers at all levels.” Personalized Medicine, matching a specific patient to a similar patient group, will be realized when the entirety of factors affecting a person’s health are considered. Then disease prevention and treatment can be tailored around their unique characteristics. By seamlessly integrating digital health data of all types, CereHealth’s technologies enable medical professionals (and researchers) to advise with precision and accuracy the best diagnostic outcome leading to the right treatment for the right patient at the right time in their lives. About CereHealth CereHealth is a data analytics technology company that provides Medical Analytics as a Service (MAaaS), enabling doctors, research scientists and others serving the healthcare community to quickly make more-informed decisions regarding patient-specific treatments for a higher likelihood of success to improve outcomes and patients’ quality of life. CereHealth is a leader in multivariable analysis of quantitative biomarkers for central nervous system (CNS) disorders with 2 patents on neuroimaging database systems and methods (and 1 patent pending), and a proprietary growing database of more than one million structured patient datapoints that include neuro imaging, cognitive assessments, detailed clinical history, and blood biomarkers. Though our structured database focuses on CNS disorders, our software is not limited to a disease, brain region, or any biomarker. To learn more about CereHealth’s MAaaS solutions, including scheduling a live demonstration visit us at ceremetrix.io. Contact Details CereHealth Corp. Shane Quint, Chief Technology Officer +1 303-282-4702 squint@cerescan.com Company Website https://ceremetrix.io/

May 04, 2021 07:00 AM Mountain Daylight Time

ZOE Announces $53M Total Raise From Investors Including Fund Backed By Top Scientists, and Two-Time Super Bowl Champion Eli Manning

ZOE

Healthcare science company ZOE announced today it has raised $53M in total funding to transform how individuals eat with a first-of-its-kind at-home test kit and personalized advice program. ZOE decodes each customer’s unique biological responses to food, and guides them on how to eat to maximize long-term health. The program uses machine learning combined with the world’s largest nutrition research studies. These funds will allow ZOE to meet the dramatic rise in customer demand since it launched a few months ago, and serve millions of people in search of a sustainable and science-backed approach to healthy eating. Addressing high rates of obesity, metabolic disease, and nutritional confusion, ZOE launched its first product in September 2020 after three years in stealth carrying out the world’s largest in-depth nutrition and microbiome study with scientists from Harvard, King’s College London, Mass General Hospital and Stanford. The test kit analyzes users’ gut health, as well as blood fat and blood sugar responses to food and uses these insights to provide daily, personalized nutrition guidance. Demand is high and ZOE is currently in waitlist-mode. Interim clinical trial results reveal participants experienced more energy (90%), felt less hunger (80%) and lost an average of 11 pounds after three months of following their personalized plan. Today’s B round of over $20M brings cash on the balance sheet to $40M. This round of financing is led by Ahren Innovation Capital (“Ahren”), whose Science Partners include two Nobel laureates. Sir Gregory Winter CBE FRS FMedSci and Nobel Prize winner for Chemistry said: “We were interested both by the approach taken by ZOE, in which they are applying machine learning to large scale population data, and by their published results, in which they are mapping out associations between diet, health and the gut microbiome.” Additional participants in this financing include two-time Super Bowl Champion and MVP Eli Manning, two-time Super Bowl Champion and award-winning sportscaster Ositadimma "Osi" Umenyiora, Accomplice (the fund behind AngelList, DraftKings, PillPack, and WHOOP), THVC and Daphni. Umenyiora said, “I'm really excited to invest in ZOE. As an athlete, I know how much eating the right food changes how I feel and how I perform.” The funds from the investment will be used to speed up the rollout of the ZOE program. Currently, the program is only available in the US, but a launch is intended in the UK in 2021 and further geographies in 2022. ZOE is continuing to hire rapidly, including in engineering and science, where its expertise spans from microbiome and nutrition to metabolic research and machine learning. Commenting on the investment, George Hadjigeorgiou, co-founder and President of ZOE, said: "We started ZOE because we believe that everyone has a right to understand how their body responds to food so they can make their own decisions and be in control of their health. We are thrilled to be partnering with a distinguished group of new and existing investors to continue on our mission to help people live healthier and happier lives.” “After 4 years of research and results published in the world’s leading medical journals, we are delighted to accelerate the launch of the ZOE program because we believe people need our help,” said Jonathan Wolf, co-founder and CEO of ZOE. “Ahren Innovation Capital, Eli Manning and Osi Umenyiora’s backing of ZOE further validates the belief held by leaders across diverse industries that we can have a powerful impact on our health through in-depth, personalized insights into our biology.” Science Supported with Multiple Papers Published in Top Peer-Reviewed Journals Experiencing rapid revenue growth and forecasting double-digit millions of revenue in its first year of sales, ZOE uses a data-driven approach to tackling global health issues. The company combines artificial intelligence, digital technologies and collaboration with world-leading scientists. ZOE’s research has led to over a dozen peer reviewed studies in high impact journals over the last year, including multiple papers in leading science journals such as Nature Medicine. In March 2020 at the onset of the pandemic, the ZOE team felt compelled to help and responded by developing and launching an app in just four sleepless days and nights, built on their existing technologies. The free ZOE Covid Study app, which is a non-profit initiative, now has more than 4.5M users across the UK, US and Sweden, calculating levels of COVID in real-time and sharing anonymous data with researchers across the world. Scientists working with ZOE have published dozens of scientific papers as a result, from understanding COVID symptoms to data on vaccine effectiveness and COVID’s long-term effects. Long-term, ZOE intends to use the app to support wider public health initiatives. About ZOE ZOE is a healthcare science company helping people understand their body’s responses to food. By using machine learning combined with large scale human studies, ZOE is decoding the impact of nutrition on health. ZOE leads the PREDICT Studies and the ZOE COVID Study, which are the world’s largest community powered research programs of their kind in nutrition and COVID-19 respectively. Located in London and Boston, ZOE was founded by Professor Tim Spector of King’s College London, data science leader Jonathan Wolf and entrepreneur George Hadjigeorgiou. ZOE was named one of the Deloitte Fast 50 Rising Stars in 2019 for the company’s contribution to science enabled by technology and machine learning. For more information on ZOE’s mission and science, visit joinzoe.com. Recently Published Nutrition Studies Postprandial glycaemic dips predict appetite and energy intake in healthy individuals, Nature Metabolism,April 12, 2021 Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals, Nature Medicine, January 11, 2021 Human postprandial responses to food and potential for precision nutrition, Nature Medicine, June 11, 2020 About Ahren Innovation Capital Ahren Innovation Capital is an investment institution that supports transformational companies at the intersection of deep tech and deep science that will penetrate, or create, massive markets. Ahren is a unique partnership of investment talent and best-in-class commercial scientists whose technologies are today valued in excess of $100BN combined. Ahren believes in taking asymmetric, considered, risk that will deliver superior rewards – capturing a generational opportunity to provide smart capital to deep technology. With a philosophy espousing the importance of relationships and trust, Ahren provides both patient and active capital to exceptional founders and teams, empowering them to succeed. For more information on Ahren Innovation Capital, visit ahreninnovationcapital.com. Contact Details ZOE Fiana Tulip +1 817-691-3031 fiana@joinzoe.com Company Website https://www.joinzoe.com

May 04, 2021 07:53 AM Eastern Daylight Time

Image

1 ... 280 281 282 283 284 ... 310